fda on tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Day 4: Zepbound (Tirzepatide –
Description
Semaglutide for clinician-supervised weight management, physician-prescribed after provider review
Obesity and Type 2 Diabetes has an increasing prevalence worldwide, presenting a major health challenge
A new European study links suspected nerve damage to severe cases involving prolonged vomiting and vitamin deficiencies.
The GLP-1 market is projected to exceed 100B USD by 2030
